Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal angiopoietin dysbalance

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Khairoun, Meriem ^a   Van Den Heuvel, Mieke ^b   Van Den Berg, Bernard M ^a   Sorop, Oana ^b   De Boer, Rients ^a   Van Ditzhuijzen, Nienke S ^b   Bajema, Ingeborg M ^a   Baelde, Hans J ^a   Zandbergen, Malu ^a   Duncker, Dirk J ^b   Rabelink, Ton J ^a   Reinders, Marlies E J ^a   Van Der Giessen, Wim J ^b   Rotmans, Joris I ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; VON WILLEBRAND FACTOR; ANGIOPOIETIN; BIOLOGICAL MARKER; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; BLOOD VESSEL INJURY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; MICROVASCULATURE; MOUTH MUCOSA; NONHUMAN; PIG; PODOCYTE; PROTEIN EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; ATHEROSCLEROSIS; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS; KIDNEY; METABOLISM; PATHOLOGY;

SUIDAE;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANGIOPOIETINS; ANIMALS; ATHEROSCLEROSIS; BIOMARKERS; DIABETES MELLITUS, EXPERIMENTAL; KIDNEY; KIDNEY GLOMERULUS; MALE; MICROVESSELS; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929353617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121555     Document Type: Article

References (50)

1. Cumbie BC, Hermayer KL. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag. 2007; 3: 823-32. PMID: 18200803
2. Tooke JE. Microvasculature in diabetes. Cardiovasc Res. 1996; 32: 764-71. PMID: 8915194
3. Feng D, Bursell SE, Clermont AC, Lipinska I, Aiello LP, Laffel L, et al. von Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes. Diabetes Care. 2000; 23: 1694-8. PMID: 11092294
4. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med. 2005; 22: 999-1004. PMID: 16026364
5. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006; 27: 552-8. PMID: 17045842
6. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002; 51: 3107-12. PMID: 12351455
7. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 556-63. doi: 10.1681/ASN.2010010010 PMID: 20167701
8. Edwards MS, Wilson DB, Craven TE, Stafford J, Fried LF, Wong TY, et al. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study. Am J Kidney Dis. 2005; 46: 214-24. PMID: 16112039
9. Goedhart PT, Khalilzada M, Bezemer R, Merza J, Ince C. Sidestream Dark Field (SDF) imaging: a novel stroboscopic LED ring-based imaging modality for clinical assessment of the microcirculation. Opt Express. 2007; 15: 15101-14. PMID: 19550794
10. Djaberi R, Schuijf JD, de Koning EJ, Wijewickrama DC, Pereira AM, Smit JW, et al. Non-invasive assessment of microcirculation by sidestream dark field imaging as a marker of coronary artery disease in diabetes. Diab Vasc Dis Res. 2012.
11. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage. 2012; 20: 256-60. doi: 10.1016/j.joca.2012.02.010 PMID: 22424462
12. Gerrity RG, Natarajan R, Nadler JL, Kimsey T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes. 2001; 50: 1654-65. PMID: 11423488
13. van den Heuvel M, Sorop O, Koopmans SJ, Dekker R, de VR, van Beusekom HM, et al. Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes. Am J Physiol Heart Circ Physiol. 2012; 302: H85-H94. doi: 10.1152/ajpheart.00311.2011 PMID: 21984550
14. Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauerwein H. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism. 2006; 55: 960-71. PMID: 16784971
15. Koopmans SJ, Dekker R, Ackermans MT, Sauerwein HP, Serlie MJ, van Beusekom HM, et al. Dietary saturated fat/cholesterol, but not unsaturated fat or starch, induces C-reactive protein associated early atherosclerosis and ectopic fat deposition in diabetic pigs. Cardiovasc Diabetol. 2011; 10: 64. doi: 10.1186/1475-2840-10-64 PMID: 21756316
16. Khairoun M, de Koning EJ, van den Berg BM, Lievers E, de Boer HC, Schaapherder AF, et al. Microvascular damage in type 1 diabetic patients is reversed in the first year after simultaneous pancreaskidney transplantation. Am J Transplant. 2013; 13: 1272-81. doi: 10.1111/ajt.12182 PMID: 23433125
17. Khairoun M, van der Pol P, de Vries DK, Lievers E, Schlagwein N, de Boer HC, et al. Renal ischemia-reperfusion induces a dysbalance of angiopoietins, accompanied by proliferation of pericytes and fibrosis. Am J Physiol Renal Physiol. 2013; 305: F901-F910. doi: 10.1152/ajprenal.00542.2012 PMID: 23825073
18. David S, Kumpers P, Hellpap J, Horn R, Leitolf H, Haller H, et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis. 2009; 53: 770-8. doi: 10.1053/j.ajkd.2008.11.030 PMID: 19268412
19. David S, Kumpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Boger SM, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant. 2010; 25: 2571-6. doi: 10.1093/ndt/gfq060 PMID: 20179005
20. Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, et al. SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2005; 289: F998-1004. PMID: 15900023
21. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, et al. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol. 2006; 290: F813-F820. PMID: 16278277
22. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest. 2004; 114: 679-88. PMID: 15343386
23. van der Pol P, Schlagwein N, van Gijlswijk DJ, Berger SP, Roos A, Bajema IM, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant. 2012; 12: 877-87. doi: 10.1111/j.1600-6143.2011.03887.x PMID: 22225993
24. van Ditzhuijzen NS, van den Heuvel M, Sorop O, van Duin RW, Krabbendam-Peters I, van HR, et al. Invasive coronary imaging in animal models of atherosclerosis. Neth Heart J. 2011; 19: 442-6. doi: 10. 1007/s12471-011-0187-0 PMID: 21904848
25. Paueksakon P, Revelo MP, Ma LJ, Marcantoni C, Fogo AB. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int. 2002; 61: 2142-8. PMID: 12028454
26. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag. 2008; 4: 1061-8. PMID: 19183753
27. Kuryliszyn-Moskal A, Dubicki A, Zarzycki W, Zonnenberg A, Gorska M. Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sE-selectin levels in patients with type 1 diabetes complicated by microangiopathy. Folia Histochem Cytobiol. 2011; 49: 104-10. PMID: 21526496
28. Sasongko MB, Wong TY, Nguyen TT, Cheung CY, Shaw JE, Wang JJ. Retinal vascular tortuosity in persons with diabetes and diabetic retinopathy. Diabetologia. 2011; 54: 2409-16. doi: 10.1007/s00125-011-2200-y PMID: 21625945
29. Sasongko MB, Wong TY, Donaghue KC, Cheung N, Jenkins AJ, Benitez-Aguirre P, et al. Retinal arteriolar tortuosity is associated with retinopathy and early kidney dysfunction in type 1 diabetes. Am J Ophthalmol. 2012; 153: 176-83. doi: 10.1016/j.ajo.2011.06.005 PMID: 21907319
30. Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol. 2005; 89: 480-3. PMID: 15774928
31. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med. 2005; 258: 336-43. PMID: 16164572
32. Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J Hypertens. 2005; 23: 153-64. PMID: 15643138
33. Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011; 121: 2278-89. doi: 10.1172/JCI46322 PMID: 21606590
34. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003; 9: 685-93. PMID: 12778167
35. Kim KL, Shin IS, Kim JM, Choi JH, Byun J, Jeon ES, et al. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc Res. 2006; 72: 394-402. PMID: 17054925
36. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002; 99: 11205-10. PMID: 12163646
37. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de HE, Bruijn JA. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 2004; 43: 636-50. PMID: 15042541
38. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007; 71: 637-45. PMID: 17264876
39. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999; 48: 2229-39. PMID: 10535459
40. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006; 69: 1654-61. PMID: 16541023
41. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 2003; 9: 1545-64. PMID: 12871067
42. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000; 58: 251-9. PMID: 10886570
43. Ishidoya S, Ogata Y, Fukuzaki A, Kaneto H, Takeda A, Orikasa S. Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats. J Urol. 2002; 167: 1503-7. PMID: 11832778
44. Barnes JL, Mitchell RJ, Torres ES. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J Histochem Cytochem. 1995; 43: 895-905. PMID: 7642963
45. Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME, et al. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia. 2007; 50: 1315-26. PMID: 17415547
46. Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol. 2009; 296: F118-F126. doi: 10.1152/ajprenal.00110.2008 PMID: 18971213
47. Taneja D, Thompson J, Wilson P, Brandewie K, Schaefer L, Mitchell B, et al. Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res. 2010; 51: 1464-70. doi: 10.1194/jlr.M002972 PMID: 20110440
48. Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol. 2011; 179: 1179-87. doi: 10.1016/j.ajpath.2011.05.016 PMID: 21723246
49. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000; 26: 254-64. PMID: 11011217
50. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989; 38: 1077-81. PMID: 2670639